MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts - KTRE.com | Lufkin and Nacogdoches, Texas

MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts

MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts

Summary

GlobalData has released its medical devices report, "MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts". The report provides in-depth insight into the use of DEB in the European Union (EU) for coronary and peripheral applications in the lower extremity including in-stent restenosis, bifurcation lesions, small vessel disease, femoropopliteal artery and below-the-knee lesions, chronic total occlusions, acute myocardial infarction and lesions in diabetics.

The DEB market in the five major EU countries including France, Germany, Italy, Spain and the UK was assessed to identify and determine whether the current unmet needs are addressed, understand the challenges of DEB angioplasty and evaluate the current and future adoption of DEB for select coronary and peripheral indications. The EU sales expectations are discussed through careful analysis of adoption patterns of using DEB in clinical practice.

Clients can use this report to better understand the Scope of this technology and for strategic planning to explore opportunities in this dynamic market. The report also provides insights into the competitive landscape, the marketed and pipeline DEB products, the current and emerging players and comparative market analysis of different types of interventional techniques used to treat coronary and peripheral artery disease. This report is built using data and information sourced from secondary sources and primary research interviews and survey with leading Interventional Cardiologists and Interventional Radiologists, with in-house analysis conducted by GlobalData's team of industry experts.

Scope

- An overview of coronary artery disease and peripheral artery disease in the lower extremity, which includes epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.
- Annualized total drug-eluting balloon market revenue by type of disease, annual cost of disease and drug-eluting balloons adoption pattern and procedure data in the EU from 2010-2012 and forecast for seven years to 2019.
- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, evaluating market access in the five major EU countries covered in the report, and implications of the drug-eluting balloon market.
- Pipeline analysis: comprehensive data split across different stages of development, emerging trends and DEB designs in development, including investigation of DEB coating technology, antiproliferative agent used, balloon and catheter design and durability.
- Analysis of the current and future market competition in the EU drug-eluting balloon market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the DEB market in the EU.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the EU DEB market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the EU DEB market by disease and indication from 2010-2019.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 8
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 26
2.1 Catalyst 27
3 Disease Overview 29
3.1 Overview 29
3.1.1 Coronary Artery Disease 29
3.1.2 Peripheral Artery Disease 29
3.2 Anatomy and Physiology 30
3.2.1 Coronary Arteries 30
3.2.2 Peripheral Arteries of the Lower Extremity 31
3.3 Pathophysiology 33
3.3.1 Coronary Artery Disease 33
3.3.2 Peripheral Artery Disease 34
3.4 Clinical Presentation 35
3.4.1 Symptoms 35
3.4.2 Risk Factors 38
3.4.3 Disease Classification 39
3.4.4 Diagnosis 40
3.4.5 Clinical Outcomes 43
3.5 Epidemiology 76
3.5.1 Coronary Artery Disease 76
3.5.2 Peripheral Artery Disease 79
3.6 Economic Impact of Coronary and Peripheral Artery Disease 82
3.6.1 Cost of Coronary Artery Disease 82
3.6.2 Cost of Peripheral Artery Disease 83
3.6.3 Treatment Costs of Coronary and Peripheral Artery Disease 84
4 Competitive Assessment 87
4.1 Overview 87
4.2 Product Profiles by Company 89
4.2.1 Aachen Resonance 90
4.2.2 B. Braun 92
4.2.3 Biotronik 99
4.2.4 Blue Medical 102
4.2.5 Cardionovum 108
4.2.6 C.R. Bard 114
4.2.7 Concept Medical Research 120
4.2.8 Cook Medical 124
4.2.9 Eurocor 126
4.2.10 Medrad (Bayer Healthcare) 141
4.2.11 Medtronic 143
4.2.12 Minvasys 151
5 Unmet Needs 154
5.1 Need for Better Clinical Outcomes in Specific Lesions 154
5.1.1 Chronic Total Occlusions 154
5.1.2 Small-Vessel Coronary Lesions 155
5.1.3 Long Lesions 155
5.1.4 Heavily-Calcified and Uncrossable/Undilatable Lesions 156
5.1.5 Bifurcation Lesions 156
5.2 Need for Better Revascularization of the Femoropopliteal Artery 157
5.3 Difficulty in Treating the Infrapopliteal Artery 159
5.4 Eliminating Mechanisms of Failure with Balloon Angioplasty 160
5.5 Addressing Challenges of Stenting 162
5.5.1 Risk of Post-Procedural Complications 162
5.5.2 In-Stent Restenosis 164
5.5.3 Stent-In-Stent Procedures 165
5.5.4 Prolonged Dual Antiplatelet Therapy 166
5.5.5 Lack of Homogenous Drug Distribution 167
5.5.6 Delayed Healing 167
5.5.7 Stent Fracture 168
5.5.8 Negative Vessel Remodeling 169
5.5.9 Long-Term Vessel Patency 170
5.6 Need for Effective Therapy for Specific Patient Populations 170
5.7 Lack of Clinical Data 171
5.8 Addressing the Complications of Bypass Surgery 171
5.9 Need to Improve Medical Therapy 172
5.10 Comparative Studies on Exercise Therapy for PAD 173
6 Pipeline Products 174
6.1 Overview 174
6.2 Pipeline by Stage of Development 175
6.3 Pipeline Product Profiles 177
6.3.1 NF-?B Decoy Oligo DEB 177
6.3.2 Drug-Coated AngioSculpt 179
6.3.3 BioPath 182
6.3.4 BioStream 183
6.3.5 Boston Scientific Drug-Coated Balloon 184
6.3.6 Coroflex DEBlue 185
6.3.7 Covidien Drug-Coated Balloon 187
6.3.8 Caliber Therapeutics DEB 189
6.3.9 Elixir Medical Corporation DCB 190
6.3.10 LifeTech Scientific Corporation DEB 190
6.3.11 Micell Technologies Drug-Coated Balloon 190
6.3.12 Drug-Coated Chocolate DEB 192
6.3.13 Passeo-18 Lux 194
6.3.14 Vascular Nanotransfer Technologies Drug-Coated Balloon 195
6.3.15 WOMBAT DCB 196
7 Clinical Trial Analysis 198
7.1 Overview 198
7.2 Clinical Trials to Watch 198
7.2.1 Drug-Eluting Balloons 198
7.2.2 Vascular Stents 212
8 Industry Overview 217
8.1 Procedure Trends 217
8.1.1 Factors Contributing to the Rise of Coronary and Peripheral Interventions 217
8.1.2 Coronary Artery Disease 218
8.1.3 Peripheral Artery Disease 219
8.2 Physician Decision-Making Process 221
8.3 Market Access 223
8.3.1 Regulatory Process 224
8.3.2 Adoption 226
8.3.3 Reimbursement Trends in the EU 228
8.4 Regulatory Issues/Recalls 233
8.4.1 Regulatory Issues 233
8.4.2 Product Recalls 233
8.5 Mergers and Acquisitions/Partnerships 234
8.5.1 Biosensors International and Eurocor 234
8.5.2 Boston Scientific Corporation and Guidant Corporation 234
8.5.3 Covidien and ev3, CV Ingenuity 235
8.5.4 C.R. Bard and Lutonix 235
8.5.5 Micell Technologies and Maxcor Lifescience 236
8.5.6 Medrad and Bayer 236
8.5.7 Medtronic and Invatec 237
9 Current and Future Players 238
9.1 Overview 238
9.2 Trends in Corporate Strategy 239
9.3 Company Profiles 242
9.3.1 Aachen Resonance 242
9.3.2 AnGes MG 243
9.3.3 AngioScore 245
9.3.4 AVIDAL Vascular 247
9.3.5 B. Braun 249
9.3.6 Biosensors International 251
9.3.7 Biotronik 253
9.3.8 Blue Medical 255
9.3.9 Boston Scientific Corporation 257
9.3.10 Caliber Therapeutics 259
9.3.11 Cardionovum 261
9.3.12 Concept Medical Research 263
9.3.13 Cook Medical 265
9.3.14 Covidien 267
9.3.15 C.R. Bard 269
9.3.16 Elixir Medical Corporation 271
9.3.17 Eurocor 273
9.3.18 LifeTech Scientific Corporation 275
9.3.19 Medtronic 277
9.3.20 Micell Technologies 279
9.3.21 Minvasys 280
9.3.22 TriReme Medical 282
9.3.23 Vascular Nanotransfer Technologies 284
10 Market Drivers, Opportunities, Barriers and Substitutes 286
10.1 Market Drivers 286
10.1.1 Rising Prevalence of Disease 287
10.1.2 Viable Treatment for Select Indications 288
10.1.3 No Metal Left Behind 293
10.1.4 Avoid Stent-in-Stent Procedures 294
10.1.5 Reduce the Need for Prolonged Dual Antiplatelet Therapy 295
10.1.6 Enhanced Vessel Healing and Better Patency 295
10.1.7 Technical Feasibility of Future Interventions 296
10.1.8 DEB as an Adjunctive Therapy 297
10.1.9 Limb Amputation 297
10.1.10 Cost Savings 298
10.1.11 Availability of Long-Term and Cost-Effective Data 299
10.1.12 Launch of DEB in the US 299
10.2 Opportunities 300
10.2.1 Improve DEB Design 300
10.2.2 DEB Hybrid Systems (DEB + Stent) 304
10.2.3 Target Indications Where Stenting is Not Satisfactory 304
10.2.4 Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries 307
10.2.5 Target Challenging Patient Populations 309
10.2.6 Launch DEB in the Japanese Market 310
10.2.7 Emerging Markets 310
10.3 Market Barriers 311
10.3.1 Slow Adoption 311
10.3.2 High Selling Prices 315
10.3.3 Lack of Reimbursement 316
10.3.4 US FDA Regulatory Challenges 317
10.3.5 Healthcare Cost-Cutting and Reimbursement 318
10.3.6 Availability of Venture Capital 319
10.3.7 Medical Device Excise Tax 320
10.4 Market Substitutes 320
10.4.1 Vascular Stents 320
10.4.2 Liquid Drug Delivery Catheter 324
11 Drug-Eluting Balloon Market Analysis 327
11.1 Global Market Overview 327
11.2 Market Analysis by Type of Disease 328
11.2.1 Coronary Artery Disease 328
11.2.2 Peripheral Artery Disease in the Lower Extremity 329
11.3 Market Distribution by Indication 332
11.4 Primary Versus Adjunctive Therapy 334
11.5 Comparative Market Analysis 336
11.5.1 Coronary Artery Disease 336
11.5.2 Peripheral Artery Disease in the Lower Extremity 338
12 Country Outlooks & Forecasts 340
12.1 Overview 340
12.2 France 342
12.2.1 Overview 342
12.2.2 Market Analysis 342
12.3 Germany 344
12.3.1 Overview 344
12.3.2 Market Analysis 344
12.4 Italy 348
12.4.1 Overview 348
12.4.2 Market Analysis 348
12.5 Spain 351
12.5.1 Overview 351
12.5.2 Market Analysis 351
12.6 United Kingdom 353
12.6.1 Overview 353
12.6.2 Market Analysis 353
13 Appendix 356
13.1 Bibliography 356
13.2 Abbreviations 382
13.3 Report Methodology 386
13.3.1 Overview 386
13.3.2 Coverage 386
13.3.3 Secondary Research 386
13.3.4 Forecasting Methodology 387
13.4 Physicians and Specialists Included in this Study 389
13.5 Physician Survey 392
13.6 About the Authors 393
13.6.1 Analysts 393
13.6.2 Global Head of Healthcare 394
13.7 About MediPoint 395
13.8 About GlobalData 395
13.9 Disclaimer 395

List of Tables

Table 1: Classification Systems for Determining the Severity of PAD Symptoms 37
Table 2: Risk Factors Associated with CAD and PAD 38
Table 3: Types of Atherosclerotic Lesions 40
Table 4: Treatment Guidelines to Improve the Symptoms of CAD* 45
Table 5: TASC II Classification of Iliac Artery Lesions 46
Table 6: TASC II Classification of Femoropopliteal Artery Lesions 47
Table 7: TASC II Classification of Infrapopliteal Artery Lesions 48
Table 8: Types of Coronary Artery Bypass Grafting 59
Table 9: Complications of Coronary/Peripheral Artery Bypass Surgery 60
Table 10: Indications for Using Drug-Eluting Balloons 64
Table 11: Drug-Eluting Balloon Coating Characteristics 66
Table 12: Drugs Incorporated Into Drug-Eluting Stents 69
Table 13: Types of Lesions Treated Using Atherectomy 72
Table 14: Prevalence of CAD in the Population Age ?65 Years in the EU (millions), 2010–2019 77
Table 15: Prevalence of PAD in the Population Age ?65 Years in the EU (millions), 2010–2019 79
Table 16: Direct and Indirect Healthcare Costs 82
Table 17: Healthcare Expenditures ($bn) for CAD in the Five Major EU Countries, 2006 83
Table 18: Healthcare Expenditures ($bn) for PAD in the EU 83
Table 19: US Mean Hospital Costs* for Coronary and Peripheral Revascularization Procedures, 2010–2019 ($US) 85
Table 20: EU DEB Market ($m) for Treating Coronary and Peripheral Artery Disease, 2012 87
Table 21: Marketed DEB Products 89
Table 22: Elutax SV Product Portfolio 90
Table 23: Elutax SV SWOT Analysis, 2013 92
Table 24: SeQuent Please Product Portfolio 93
Table 25: SeQuent Please SWOT Analysis, 2013 98
Table 26: Pantera Lux Product Portfolio 99
Table 27: Pantera Lux SWOT Analysis, 2013 101
Table 28: Pioneer Product Portfolio 102
Table 29: Pioneer SWOT Analysis, 2013 104
Table 30: Protégé Product Portfolio 105
Table 31: Protégé SWOT Analysis, 2013 108
Table 32: Restore DEB Product Portfolio 109
Table 33: Restore DEB SWOT Analysis, 2013 110
Table 34: Legflow DEB Product Portfolio 111
Table 35: Legflow DEB SWOT Analysis, 2013 113
Table 36: Other DEB Products Developed by Cardionovum 114
Table 37: Lutonix Product Portfolio 115
Table 38: Lutonix SWOT Analysis, 2013 120
Table 39: Magic Touch Product Portfolio 121
Table 40: Magic Touch SWOT Analysis, 2013 123
Table 41: Advance 18 PTX Product Portfolio 124
Table 42: Advance 18 PTX SWOT Analysis, 2013 126
Table 43: Dior Product Portfolio 127
Table 44: Dior SWOT Analysis, 2013 133
Table 45: Freeway Family of DEB Product Portfolio 134
Table 46: Freeway Family of DEB SWOT Analysis, 2013 137
Table 47: Magical Product Portfolio 138
Table 48: Magical SWOT Analysis, 2013 140
Table 49: Cotavance Product Portfolio 141
Table 50: Cotavance SWOT Analysis, 2013 143
Table 51: IN.PACT Family DEB Product Portfolio 144
Table 52: IN.PACT SWOT Analysis, 2013 151
Table 53: Danubio Product Portfolio 152
Table 54: Danubio SWOT Analysis, 2013 153
Table 55: Global DEB Pipeline Products 176
Table 56: NF-?B Decoy Oligo DEB SWOT Analysis, 2013 179
Table 57: AngioSculpt SWOT Analysis, 2013 181
Table 58: BioPath SWOT Analysis, 2013 183
Table 59: BioStream SWOT Analysis, 2013 184
Table 60: Boston Scientific DEB SWOT Analysis, 2013 185
Table 61: Coroflex DEBlue SWOT Analysis, 2013 187
Table 62: Covidien DCB SWOT Analysis, 2013 189
Table 63: Micell Technologies' DCB SWOT Analysis, 2013 191
Table 64: Drug-Coated Chocolate DEB SWOT Analysis, 2013 193
Table 65: Passeo-18 Lux SWOT Analysis, 2013 195
Table 66: Vascular Nanotransfer Technologies DCB SWOT Analysis, 2013 196
Table 67: WOMBAT DCB SWOT Analysis, 2013 197
Table 68: Aachen Resonance Company Profile 242
Table 69: Aachen Resonance, Marketed DEB Product 243
Table 70: Aachen Resonance SWOT Analysis, 2013 243
Table 71: AnGes MG Company Profile 244
Table 72: AnGes MG, Pipeline DEB Product 245
Table 73: AnGes MG SWOT Analysis, 2013 245
Table 74: AngioScore Company Profile 246
Table 75: AngioScore, Pipeline DEB Product 246
Table 76: AngioScore SWOT Analysis, 2013 247
Table 77: AVIDAL Vascular Company Profile 247
Table 78: AVIDAL Vascular, Pipeline DEB Product 248
Table 79: AVIDAL Vascular SWOT Analysis, 2013 249
Table 80: B. Braun Company Profile 249
Table 81: B. Braun, Marketed and Pipeline DEB Products 250
Table 82: B. Braun SWOT Analysis, 2013 251
Table 83: Biosensors International Company Profile 252
Table 84: Biosensors International, Pipeline DEB Products 252
Table 85: Biosensors International SWOT Analysis, 2013 253
Table 86: Biotronik Company Profile 254
Table 87: Biotronik, Marketed and Pipeline DEB Products 254
Table 88: Biotronik SWOT Analysis, 2013 255
Table 89: Blue Medical Company Profile 256
Table 90: Blue Medical, Marketed DEB Products 257
Table 91: Blue Medical SWOT Analysis, 2013 257
Table 92: Boston Scientific Corporation Company Profile 258
Table 93: Boston Scientific Corporation, Pipeline DEB Product 258
Table 94: Boston Scientific Corporation SWOT Analysis, 2013 259
Table 95: Caliber Therapeutics Company Profile 259
Table 96: Caliber Therapeutics, Pipeline DEB Product 260
Table 97: Caliber Therapeutics SWOT Analysis, 2013 261
Table 98: Cardionovum Company Profile 261
Table 99: Cardionovum, Marketed and Pipeline DEB Products 262
Table 100: Cardionovum SWOT Analysis, 2013 263
Table 101: Concept Medical Research Company Profile 263
Table 102: Concept Medical Research, Marketed DEB Product 264
Table 103: Concept Medical Research SWOT Analysis, 2013 265
Table 104: Cook Medical Company Profile 265
Table 105: Cook Medical, Marketed DEB Product 266
Table 106: Cook Medical SWOT Analysis, 2013 267
Table 107: Covidien Company Profile 268
Table 108: Covidien, Pipeline DEB Product 268
Table 109: Covidien SWOT Analysis, 2013 269
Table 110: C.R. Bard Company Profile 269
Table 111: C.R. Bard, Marketed DEB Products 270
Table 112: C.R. Bard SWOT Analysis, 2013 271
Table 113: Elixir Medical Corporation Company Profile 271
Table 114: Elixir Medical Corporation, Pipeline DEB Product 272
Table 115: Elixir Medical Corporation SWOT Analysis, 2013 272
Table 116: Eurocor Company Profile 273
Table 117: Eurocor, Marketed DEB Products 274
Table 118: Eurocor SWOT Analysis, 2013 274
Table 119: LifeTech Scientific Corporation Company Profile 275
Table 120: LifeTech Scientific, Pipeline DEB Product 276
Table 121: LifeTech Scientific SWOT Analysis, 2013 276
Table 122: Medtronic Company Profile 277
Table 123: Medtronic, Marketed DEB Products 278
Table 124: Medtronic SWOT Analysis, 2013 278
Table 125: Micell Technologies Company Profile 279
Table 126: Micell Technologies, Pipeline DEB Product 280
Table 127: Micell Technologies SWOT Analysis, 2013 280
Table 128: Minvasys Company Profile 281
Table 129: Minvasys, Marketed DEB Product 281
Table 130: Minvasys SWOT Analysis, 2013 282
Table 131: TriReme Medical Company Profile 282
Table 132: TriReme Medical, Pipeline DEB Product 283
Table 133: TriReme Medical SWOT Analysis, 2013 284
Table 134: Vascular Nanotransfer Technologies Company Profile 284
Table 135: Vascular Nanotransfer Technologies, Pipeline DEB Product 285
Table 136: Vascular Nanotransfer Technologies SWOT Analysis, 2013 285
Table 137: EU Coronary and Peripheral DEB Market ($m) Forecast, 2010–2019 328
Table 138: EU DEB Market ($m) for Treating PAD in the Lower Extremity, 2010–2019 329
Table 139: Percent of Patients with CAD or PAD Receiving Stenting with DEB Angioplasty, EU, 2012 and 2018 (N=56) 334
Table 140: DEB Sales ($m) Forecast for France, 2010–2019 342
Table 141: DEB Sales ($m) Forecast for Germany, 2010–2019 345
Table 142: DEB Sales ($m) Forecast for Italy, 2010–2019 348
Table 143: DEB Sales ($m) Forecast for Spain, 2010–2019 352
Table 144: DEB Sales ($m) Forecast for UK, 2010–2019 354
Table 145: Physicians Surveyed, By Country 39

1.2 List of Figures
Figure 1: Coronary Arteries of the Human Heart 30
Figure 2: Peripheral Arteries of the Lower Extremity 31
Figure 3: Pathophysiology of Coronary Artery Disease 33
Figure 4: Pathophysiology of Peripheral Artery Disease 34
Figure 5: Treatment Modalities – Coronary Artery Disease 50
Figure 6: Percent of Patients with CAD Who Receive Each Therapy Option Only, EU, 2012 and 2019 (N=32) 51
Figure 7: Treatment Modalities – Peripheral Artery Disease 52
Figure 8: Percent of Patients with PAD Who Receive Each Therapy Option Only, EU, 2012 (N=24) 53
Figure 9: Percent of Patients with PAD Who Receive Each Therapy Option Only, EU, 2012 (N=24) 54
Figure 10: Drug-Eluting Balloon 62
Figure 11: Types of Stents Used to Treat CAD and PAD 68
Figure 12: Bare Metal Stent 68
Figure 13: Drug-Eluting Stent 69
Figure 14: Covered Stents 70
Figure 15: Bioabsorbable Stent – Remedy 71
Figure 16: Types of Atherectomy 73
Figure 17: Prevalence of CAD in the Population Age ?65 Years in the EU (millions), 2010–2019 77
Figure 18: Prevalence of PAD in the Population Age ?65 Years in the EU (millions), 2010–2019 80
Figure 19: Healthcare Expenditures ($bn) for PAD in the EU 84
Figure 20: US Mean Hospital Costs* for Coronary and Peripheral Revascularization Procedures, 2010–2019 ($US) 86
Figure 21: EU DEB Market Share for Treating Peripheral Artery Disease in the Lower Extremity, 2012 88
Figure 22: Image of the Protégé DEB 106
Figure 23: Percent of CAD and PAD Patients with Acute Vessel Recoil After Standard Balloon Angioplasty, EU, 2012 and 2018 (N=56) 161
Figure 24: Percent of CAD and PAD Patients with Thrombosis After Stenting, EU, 2012 and 2018 (N=56) 163
Figure 25: Percent of CAD and PAD Patients with ISR, EU, 2012 and 2018 (N=56) 164
Figure 26: Percent of CAD and PAD Patients Who Receive Stent-In-Stent Procedures, EU, 2012 and 2018 (N=56) 166
Figure 27: Percent of CAD and PAD Patients with Stent Fracture, EU, 2012 and 2018 (N=56) 169
Figure 28: Global DEB Pipeline Products by Stage of Development, 2013 175
Figure 29: AngioSculpt Scoring Balloon Expansion Profile 180
Figure 30: Drug-Coated Chocolate DEB 192
Figure 31: Population (? 65 years) of CAD Patients Receiving Interventional Procedures, EU*, 2010–2019 219
Figure 32: Population (? 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, EU*, 2010–2019 220
Figure 33: Population (? 65 years) with PAD Receiving DEB Angioplasty in the Peripheral Arteries in the Lower Extremity, EU*, 2010–2019 221
Figure 34: DEB Market for Treating CAD and PAD in the Lower Extremity, Company Share (%), 2012 238
Figure 35: DEB Market for Each Type of Disease, Company Share (%), 2012 240
Figure 36: Importance of Each Therapy Attribute in Adopting DEB for the Treatment of CAD and PAD, Global, 2012 (N=112) 301
Figure 37: EU DEB Market ($m) for Treating Coronary Artery Disease and Peripheral Artery Disease in the Lower Extremity, 2010-2019 327
Figure 38: EU DEB Market ($m) for Treating PAD in the Lower Extremity, 2010–2019 330
Figure 39: EU DEB Market Share for Peripheral Artery Revascularization in the Lower Extremity , 2012 and 2019 331
Figure 40: EU DEB Market Distribution (%) by Indication, 2012 and 2018 (N=56) 333
Figure 41: Percent of Patients with CAD Receiving Each Type of Interventional Technique Only, EU, 2018 (N=32) 337
Figure 42: Percent of Patients with Lower Limb PAD Receiving Each Type of Interventional Technique Only, EU, 2018 (N=24) 338
Figure 43: EU DEB Market Revenue ($m), 2012 and 2019 341
Figure 44: French DEB Market ($m) for Coronary and Peripheral Applications, 2010–2019 343
Figure 45: German DEB Market ($m) for Coronary and Peripheral Applications, 2010–2019 345
Figure 46: Italian DEB Market ($m) for Coronary and Peripheral Applications, 2010–2019 349
Figure 47: Spanish DEB Market ($m) for Coronary and Peripheral Applications, 2010–2019 352
Figure 48: UK DEB Market ($m) for Coronary and Peripheral Applications, 2010–2019 355

Companies Mentioned

Aachen Resonance
AnGes MG
AngioScore
AVIDAL Vascular
B. Braun
Biosensors International
Biotronik
Blue Medical
Boston Scientific Corporation
Caliber Therapeutics
Cardionovum
Concept Medical Research
Cook Medical
Covidien
C.R. Bard
Elixir Medical Corporation
Eurocor
LifeTech Scientific Corporation
Medtronic
Micell Technologies
Minvasys
TriReme Medical
Vascular Nanotransfer Technologies

Read the full report:
MediPoint: Drug-Eluting Balloons - EU Analysis and Market Forecasts
http://www.reportbuyer.com/pharma_healthcare/diseases/medipoint_drug_eluting_balloons_eu_analysis_market_forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
KTRE logo

KTRE

358 TV Road,
Pollok TX 75969

FCC Public File
publicfile@ktre.com
936-853-8639
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KTRE. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.